0001415889-24-004473.txt : 20240220 0001415889-24-004473.hdr.sgml : 20240220 20240220184804 ACCESSION NUMBER: 0001415889-24-004473 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240215 FILED AS OF DATE: 20240220 DATE AS OF CHANGE: 20240220 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dubow Adam CENTRAL INDEX KEY: 0001744507 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40431 FILM NUMBER: 24655669 MAIL ADDRESS: STREET 1: DAY ONE BIOPHARMACEUTICALS, INC. STREET 2: 2000 SIERRA POINT PARKWAY, SUITE 501 CITY: BRISBANE STATE: CA ZIP: 94005 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Day One Biopharmaceuticals, Inc. CENTRAL INDEX KEY: 0001845337 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 832415215 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501 CITY: BRISBANE STATE: CA ZIP: 94005 BUSINESS PHONE: 650 484-0899 MAIL ADDRESS: STREET 1: 2000 SIERRA POINT PARKWAY, SUITE 501 CITY: BRISBANE STATE: CA ZIP: 94005 FORMER COMPANY: FORMER CONFORMED NAME: Day One Biopharmaceuticals Holding Co LLC DATE OF NAME CHANGE: 20210209 4 1 form4-02202024_110256.xml X0508 4 2024-02-15 0001845337 Day One Biopharmaceuticals, Inc. DAWN 0001744507 Dubow Adam 2000 SIERRA POINT PARKWAY, SUITE 501 BRISBANE CA 94005 false true false false GENERAL COUNSEL 0 Common Stock 2024-02-15 4 M 0 2962 A 14390 D Common Stock 2024-02-15 4 M 0 1750 A 16140 D Common Stock 2024-02-15 4 M 0 3687 A 19827 D Common Stock 2024-02-16 4 S 0 3242 15.2481 D 16585 D Restricted Stock Unit (RSU) 2024-02-15 4 M 0 2962 0 D Common Stock 2962 32588 D Restricted Stock Unit (RSU) 2024-02-15 4 M 0 1750 0 D Common Stock 1750 19250 D Restricted Stock Unit (RSU) 2024-02-15 4 M 0 3687 0 D Common Stock 3687 55313 D Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration. The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs. The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date. /s/ Charles N. York II, as Attorney-in-Fact 2024-02-20